Latest News and Press Releases

Diamyd Medicals fas III-studie publicerad i New England Journal of Medicine En artikel med resultaten från Diamyd Medicals europeiska fas III-studie med den antigenbaserade diabetesterapin Diamyd®...

Diamyd Medical's Phase III study published in the New England Journal of Medicine An article with the results of Diamyd Medical's European Phase III study of the antigen-based diabetes therapy...

Delårsrapport I 11/12 Delårsrapport Diamyd Medical AB (publ), räkenskapsåret 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Perioden 1 september 2011 – 30 november...

Quarterly Report I 11/12 Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012 (www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY) Reporting period September 1, 2011 – November...

Prevention study with Diamyd´s diabetes vaccine fully recruited A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated...

Preventionsstudie med Diamyds diabetesvaccin fullrekryterad Totalt 50 barn från fyra års ålder med hög risk att utveckla typ 1-diabetes har inkluderats i en forskarinitierad fas II-studie,...

Annual Report 10/11 Q1 • Results from Phase I study in cancer pain shows promising safety data and relief of chronic pain Q2 • Recruitment for US Phase III study in type 1 diabetes is completed •...

Bulletin from Annual General Meeting: Diamyd Medical towards new goals At Diamyd Medical’s Annual General Meeting on December 7, Peter Zerhouni, President and CEO, commented that the past year had...

Kommuniké från bolagsstämma: Diamyd Medical mot nya mål Vid Diamyd Medicals ordinarie bolagsstämma den 7 december meddelade vd Peter Zerhouni att det gångna året har varit händelserikt och...

University of Florida Research Foundation and Diamyd Medical settle lawsuit University of Florida Research Foundation, Incorporated (“UFRF”), and Diamyd Medical AB today jointly announced that they...